Objective:Research has demonstrated that microRNA(miR)-106a is related to cisplatin resistance.We investigated the expression of miR-106a in the serum of patients with non-small cell lung cancer(NSCLC)and their sensit...Objective:Research has demonstrated that microRNA(miR)-106a is related to cisplatin resistance.We investigated the expression of miR-106a in the serum of patients with non-small cell lung cancer(NSCLC)and their sensitivity to chemotherapy by cisplatin combined with gemcitabine.Methods:Eighty-five NSCLC patients,who completed four cycles of gemcitabine and cisplatin chemotherapy,volunteered for this study and their serum samples were collected.Serum samples from 60 healthy subjects were used as controls.Real-time quantitative polymerase chain reaction(real-time q PCR)was used to quantify the level of miR-106a in the serum.Demographic and survival data of these patients were collected for the analysis.Results:The expression of miR-106a in the serum of NSCLC patients was significantly higher than that of healthy subjects(P<0.001).The expression of miR-106a was not correlated with patients'gender,age,tumor size,lymphatic metastasis,and pathological types;but was correlated with patients'tumor staging(P=0.003).After chemotherapy,serum miR-106a expression decreased in patients.The decrease in miR-106a expression in the chemotherapy-sensitive group was much higher than that in the chemotherapy-resistant group.Survival analysis shows that NSCLC patients with high expression of miR-106a have a poorer prognosis.The overall survival of NSCLC patients in the chemotherapy-sensitive group was significantly higher than that in the chemotherapy-resistant group.Conclusions:High expression of miR-106a may be involved in the development of NSCLC.Mi R-106a has significance in the prognosis of NSCLC.The level of miR-106a in the serum can be a useful parameter in screening for drug resistance during cisplatin-based chemotherapy.展开更多
文摘Objective:Research has demonstrated that microRNA(miR)-106a is related to cisplatin resistance.We investigated the expression of miR-106a in the serum of patients with non-small cell lung cancer(NSCLC)and their sensitivity to chemotherapy by cisplatin combined with gemcitabine.Methods:Eighty-five NSCLC patients,who completed four cycles of gemcitabine and cisplatin chemotherapy,volunteered for this study and their serum samples were collected.Serum samples from 60 healthy subjects were used as controls.Real-time quantitative polymerase chain reaction(real-time q PCR)was used to quantify the level of miR-106a in the serum.Demographic and survival data of these patients were collected for the analysis.Results:The expression of miR-106a in the serum of NSCLC patients was significantly higher than that of healthy subjects(P<0.001).The expression of miR-106a was not correlated with patients'gender,age,tumor size,lymphatic metastasis,and pathological types;but was correlated with patients'tumor staging(P=0.003).After chemotherapy,serum miR-106a expression decreased in patients.The decrease in miR-106a expression in the chemotherapy-sensitive group was much higher than that in the chemotherapy-resistant group.Survival analysis shows that NSCLC patients with high expression of miR-106a have a poorer prognosis.The overall survival of NSCLC patients in the chemotherapy-sensitive group was significantly higher than that in the chemotherapy-resistant group.Conclusions:High expression of miR-106a may be involved in the development of NSCLC.Mi R-106a has significance in the prognosis of NSCLC.The level of miR-106a in the serum can be a useful parameter in screening for drug resistance during cisplatin-based chemotherapy.
